Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Capromab - Cytogen Corporation

Drug Profile

Capromab - Cytogen Corporation

Alternative Names: 111In CYT 356; Capromab pendetide; CYT 356; indium (111In) labeled capromab pendetide; ProstaScint

Latest Information Update: 13 Jun 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytogen Corporation
  • Class Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Prostate cancer

Most Recent Events

  • 06 Jun 2016 Hybridyne Imaging Technologies initiates enrolment in a clinical trial in Prostate cancer (Diagnosis) in Canada
  • 02 Mar 2016 Hybridyne Imaging Technologies plans a clinical trial for diagnosis in Prostate cancer in Canada
  • 09 Jun 2015 Aytu Biosciences in-licenses capromab from Jazz Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top